COSTEM 2023 | Tackling resistance to CAR-T therapy across hematological malignancies
In this video, Michael Bishop, MD, University of Chicago, Chicago, IL, briefly discusses strategies being explored to mitigate resistance to CAR-T cells in patients with hematological malignancies, commenting on research exploring the impact of T-cell exhaustion and the tumor microenvironment. This interview took place at The 8th Congress on Controversies in Stem Cell Transplantation and Cellular Therapies (COSTEM 2023), held in Berlin, Germany.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Disclosures
Membership on a Advisory Board or Consultant: KITE/Gilead, Novartis, CRISPR Therapeutics, Autolus Therapeutics, BMS/JUNO Therapeutics, Incyte, Sana Biotechnology, Iovance Biotherapeutics, In8bio, Chimeric Therapeutics
Speakers Bureau: BMS, Kite/Gilead, Servier, AstraZeneca, ADC Therapeutics, Incyte
